Origin Energy Ltd
ORG
Woodside Energy Group Ltd
WDS
BHP Group Ltd
BHP
4
ANZ Group Holdings Ltd
ANZ
5
Westpac Banking Corp
WBC
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.